Cervical cancer is one of the few cancers that is almost entirely preventable, and yet it remains among the leading cancers killing Indian women, claiming tens of thousands of lives each year. The tragedy is double: a simple screening test catches precancerous changes years before they turn malignant, and a vaccine prevents the infection that causes most cases. India carries a disproportionate share of the global burden, concentrated among women with the least access to screening. Understanding when to start, which test to take and how often removes the confusion that keeps women away.

What causes cervical cancer

Persistent infection with high-risk types of the human papillomavirus, HPV, causes virtually all cervical cancers. HPV is extremely common, transmitted through sexual contact, and most infections clear on their own within two years. The danger lies in the minority that persist: over 10 to 20 years, persistent high-risk HPV can progress through precancerous stages (CIN) to invasive cancer. This long timeline is precisely what makes screening so powerful; there is a generous window to find and treat precancer before it becomes cancer. Smoking, multiple partners, early sexual debut, long-term oral contraceptive use, immunosuppression and high parity raise risk, but HPV persistence is the necessary cause.

Pap smear: the classic screening test

The Pap smear, cervical cytology, collects cells from the cervix during a pelvic exam for microscopic examination. It detects abnormal cells indicating precancer, not cancer itself, which is the point: treatment at the precancer stage is simple and curative. Guidelines generally recommend starting at 21, or within a few years of sexual debut, and repeating every three years if results are normal. The test is quick, mildly uncomfortable rather than painful, and widely available at government hospitals, often free under national programmes. Its limitation is sensitivity: a single Pap can miss abnormalities, which is why regular repetition matters more than any single result.

HPV testing: the modern standard

HPV DNA testing detects the virus itself and is more sensitive than cytology, catching risk earlier. Many guidelines now prefer primary HPV testing every five years for women 30 and above, with Pap used to triage positive results. Self-sampled HPV tests, where women collect their own vaginal sample, are a breakthrough for India: they bypass the pelvic exam barrier, embarrassment, discomfort, need for female providers, that keeps millions unscreened. Visual inspection with acetic acid (VIA), where the cervix is examined after vinegar application, remains the workhorse in low-resource settings: cheap, immediate, and enabling same-visit treatment. The best test is the one a woman will actually take, regularly.

Indian guidelines: when and how often

For Indian women, practical guidance converges on: begin screening by 30 at the latest (earlier with risk factors), use VIA, Pap or HPV testing as available, and repeat every three to five years depending on the test. Screening should continue through 65 if prior results were normal and adequate. Women who have had hysterectomies for non-cancer reasons may stop; those treated for precancer need closer follow-up. Importantly, screening is for women without symptoms; bleeding between periods, after intercourse or after menopause, or unusual discharge, needs prompt evaluation regardless of screening history. Government programmes offer free screening, yet uptake remains low single digits in many states, a gap awareness must close.

Vaccination: prevention before screening

The HPV vaccine prevents the infections that cause most cervical cancers and is most effective before sexual debut, recommended from age 9 to 14 as two doses, with catch-up schedules to 26 and selective use beyond. India’s indigenous vaccine has slashed costs, and school-based programmes are expanding access dramatically. Vaccinated women still need screening, since the vaccine covers the commonest but not all cancer-causing types. Together, vaccination plus screening is how countries like Australia are on track to eliminate cervical cancer; India, with its new affordable vaccine and vast primary care network, can follow.

FAQs

Is the Pap smear painful? It causes brief discomfort or pressure, not significant pain, and takes under five minutes.

Can virgins skip screening? Risk is minimal without sexual activity, but guidelines base screening on age; discuss individual timing with a doctor.

Does a positive HPV test mean cancer? No. Most positives clear spontaneously; it means closer follow-up, not a cancer diagnosis.

Cervical cancer persists in India not for lack of tools but for lack of reach. A test every few years, a vaccine in adolescence: these two interventions have eliminated this cancer elsewhere. Every Indian woman deserves to know they exist, and to be offered them without having to ask.

Compiled by the Khabar 24h Editorial Desk from publicly available sources.